Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272695 | 0.96 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL271850 | 0.96 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL272587 | 0.91 | CYP3A4 (0.49) | CYP3A4MMP2MMP13 | |
| SCHEMBL271655 | 0.88 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL273044 | 0.88 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL271439 | 0.87 | CYP3A4 (0.38) | CYP3A4 | |
| SCHEMBL271389 | 0.87 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL272476 | 0.87 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL272277 | 0.86 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL271996 | 0.86 | CYP3A4 (0.39) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2012-07-19 | — | — | US | claimed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | claimed |
| EP-1993820-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | Abbott Laboratories (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007103670-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2007-09-13 | — | — | WO | claimed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | claimed |
| US-8741938-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBVIE INC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2012-07-19 | — | — | US | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100280248-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | US | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1993820-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | Abbott Laboratories (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103670-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885MMP2 910/4885MMP13 1074/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885MMP2 910/4885MMP13 1074/4885 |
| US-20100280248-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885MMP2 910/4885MMP13 1074/4885 |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885MMP2 910/4885MMP13 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.